Avalo Therapeutics, Inc. (AVTX) Net margin 2016–2025
Avalo Therapeutics, Inc. (AVTX) net profit margin by fiscal year — reported net income divided by reported revenue.
-132642.4%FY2025 · since FY2016: -1428.6% → -132642.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -132642.4% | -124676.6 pp |
| FY2024 | -7965.8% | -6326.3 pp |
| FY2023 | -1639.5% | -1408.7 pp |
| FY2022 | -230.8% | +1332.3 pp |
| FY2021 | -1563.1% | -615.2 pp |
| FY2020 | -947.9% | -709.8 pp |
| FY2019 | -238.1% | +331.8 pp |
| FY2018 | -569.9% | -612.5 pp |
| FY2017 | 42.7% | +1471.3 pp |
| FY2016 | -1428.6% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice